Document:

Exhibit 10.2

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A
CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH
PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE
OF THE REDACTED LANGUAGE.

 

October 5, 2004

 

Mr. Reuven Ron

Yissum Research Development Company

of the Hebrew University of Jerusalem

P.O. Box 39135

Jerusalem, 91390

 

Dear Sir,

 

Re: Joint Venture for R&D Agreement

 

1.          This
is to inform you that Intec Pharma Ltd. (the “Company”) has decided to extend the Research Period as defined in the Joint
Venture for R&D Agreement between the Company and Yissum Research Development Company of the Hebrew University of Jerusalem
(“Yissum) dated June 1, 2000 (the “Agreement), for an additional term from 01/01/2004 and until December 31, 2004 (the
"Additional Research Period").

 

2.          During
the Additional Research Period Yissum shall provide the Company with additional research services (the “Additional Research”),
all in accordance with the Additional Research Plan, attached hereto as Appendix A and the Company shall finance the Additional
Research as specified in Appendix B hereto.

 

3.          The
terms of the Agreement shall apply mutatis-mutandis to the Additional Research and the Additional Research Period, except
that the intellectual property rights and any patents arising from the Research Results and Know-How of the Additional Research
only (the “Additional IP”) shall be jointly-owned by the Parties and will he registered in both their names. This section
shall not derogate from the Company's obligations to pay royalties or any other consideration with respect to the use thereof accordance
with the terms of the License.

 

Yissum shall grant
the Company an exclusive, unlimited and perpetual license to use its rights in the Additional IP, under the same terms as the License,
mutatis-mutandis (the “the Additional License”).

 

4.          In
light of considerable progress achieved during the initial Research Period under the Agreement, supported by the Company's financing,
and due to recent regulation of a patent in the name of Yissum, it is further agreed that:

 

4.1           In
the event the company grants a Sub-Licenses under the Agreement, the Company shall inform Yissum of such Sub-License within a reasonable
period of time after such Sub-License is granted, without being required to obtain Yissum's contract to such Sub-License, and without
derogating from Yissum’s right to Royalties according to the provisions of this Agreement.

 

    	 

    	 

    

  

NOTE: PORTIONS OF THIS EXHIBIT ARE
THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION
(“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE
MARKED WITH A  “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

4.2           Such
Sub-Licenses may be perpetual and the Sub-Licensees under such Sub-Licensees shall not be required to assume any undertaking towards
Yissum.

 

4.3           To
avoid any doubts, it is hereby clarified that The License granted to the Company under the Agreement is exclusive and perpetual,
applies to the Know How (including the aforesaid patent) and the Research Results under the Agreement and to any Know How and Research
Results under the Additional Research, and (ii) Yissum, as the sole owner and proprietor of the rights in and to the Patents, Know
How and Search Results, shall not grant any of rights of any kind in or to the Patents, Know How and/or Search Results unless the
Company's prior written consent is obtained.

 

4.4           At
the end of the Additional Research Period Yissum shall provide the Company with a financial report, specifying the use of financial
resources by Yissum in accordance with the Additional Research.

 

5.          By
signing this letter each party confirms that, to the best of its knowledge, all the other party's undertakings under the Agreement
were satisfactorily fulfilled and they have no claims or demands in such report.

 

Please confirm the
aforesaid by signing this letter below and returning the signed copy to our address.

 

	 	Sincerely Yours, 
	 	Zvika Joseph, CEO
	 	Intec Pharma Ltd.
	 	 
	 	/s/ Zvika Joseph

 

We hereby confirm and agree to the conditions set in this letter. 

 

	/s/ Abraham Barak	 
	Yissum Research Development Company	 
	of the Hebrew University of Jerusalem	 

 

    	2

    	 

    

  

NOTE:
PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE
COMMISSION (“COMMISSION”). SUCH  PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE
MARKED  WITH A  “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

APPENDIX A 

 

ADDITIONAL RESEARCH 

 

Research Plan for INTEC Pharma: Improvement
of the mechanical properties of the frame

 

Prof. M. Friedman

Scope: The following document describes the research
activities to be carried out at Professor Friedman's laboratory at the Hebrew University in the months August to December 2004.

 

Aim: The main goal of this stage in development of the product
is to improve the mechanical properties of the frame in order to maximize the retention of the GRDF in the stomach. Naturally,
whatever formulation comes out as having the best properties, it will have to comply with his production and assembly methods at
INTEC Pharma.

 

New formulations: Series of different formulations will
be made and tested. These series will start as close as possible to the current formulation. This might not be the best approach,
but because the short time available, we want to induce the smallest changes possible to the composition of the frame, to avoid
problems in purchase and production.

 

		I.	A series of different proportions of ethyl cellulose (EC) to Eudragit L (EudL). This will require also optimization of the
amount of triacetin for each EC/EudL combination.

 

		II.	We will try to substitute part of the triacetin with glycerol. Other plasticizers will also be tested.

 

		III.	A series of polymers will be tried as a substitute for EC, or part of the EC. For example, Eudragit RL/RS and polyvinyl acetate
will be tried.

 

		IV.	Other enteric polymers will be tried as a substitution to the EudL. For example, several Kollidon (from BASF) grades
might be useful.

 

Evaluation of the different formulations: In the first
series, we will have to use qualitative methods to evaluate the films like visual uniformity, bar and break assessment, and finally,
assemble and folding in actual GRDFs. Quantifications will be done by opening experiments. In parallel, we will develop methods
for testing the mechanical properties of the GRDF and its different components. The development of these tests and accessories
for the texture analyzer will be done in close collaboration with Stable Micro Systems Ltd. Surrey, U.K. We currently aim at two
tests: I. simple and flat tests for the frame. It could be a three-points-heading test of something similar. Each new frame formulation
will be testes with this method. II. a compression tests for the assembled GRDF. This tests, if provided predictive for GR, can
be used to monitor mechanical properties during dissolution experiment and later, for quantifying changes during shelf life.

 

    	3

    	 

    

  

NOTE:
PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY  THE
REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY
WITH THE COMMISSION AND ARE MARKED WITH A  “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

Schedule: The first series can be completed and tested by the
beginning of October (with EC and EudL and different plasticizers). Testing possible replacements for EC and/or EudL will take
additional three months (minimum), thus until the end of 2004.

 

The development of the mechanical tests, including validation
will take 3.5 months at least (middle of November). However, it is possible to complete the first and more straightforward test
for the frame a month earlier (mid October).

 

Prof. A. Hoffman

 

A plan and a schedule for the research
work at the School of Pharmacy of the Hebrew University by the laborites of Prof. Amnon Hoffman.

 

	I.	A.	 Development of a list of potential APIs that could benefit from GRDF

Timeframe: Jan.-Mar.

 

		B.	Evaluation of 3 new potential APIs in-vivo (in rats), in vitro or ex vivo. The means of evaluation will be based on the existing
knowledge or extending the knowledge about the API in terms of “absorption window”, bioavailability following continuous
duodenal infusion, stability in the stomach, pharmaco-dynamic advantages of sustained input function etc.

 

The methods that will be applied in this project will
include Ussing diffusion chambers to establish absorption windows and/or duodenal infusion in rats in order to assess pharmacokinetics
and/or pharmacodynamics of the API.

 

In addition, a suitable assay will be established (if
existing in literature) or developed for the determination and quantification of each of the APIs.

 

The screening process will progress according to the
actual findings for each API

 

Timeframe: Jan.-Dec.

 

The potential APIs that will be examined will consist
of 3 different types:

 

“[***]”

 

    	4

    	 

    

  

NOTE:
PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE
COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED
WITH A  “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

APPENDIX B 

 

FINANCING 

 

Financing for the Additional
Research in the amount of $94,250 has been provided by the Company prior to this Agreement as follows:

 

$37,000 - Paid. 

 

$37,000 - Paid. 

 

$20,250 - Paid. 

 

Additional $23,250 will be paid to Yissum upon signing
this Agreement.

 

    	5Exhibit 10.3

 

AMENDMENT

 

THIS AMENDMENT (the “Amendment”)
made on 13 day of July 2005 by and between Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”),
and Intec Pharma Ltd. (formerly Intec Pharmaceutical Partnership Ltd.) (“Intec Pharma”) (each a “Party”
and together the “Parties”).

 

WHEREAS the Parties entered into the Joint
Venture for R&D Agreement dated June 1, 2000 (the “R&D Agreement”), which was extended
and amended on October 5, 2004 (the “Extension”) (the R&D Agreement and the Extension shall collectively
be referred to as the “Agreement”); and

 

WHEREAS the Parties wish to amend the Agreement as detailed
below.

 

NOW, THEREFORE, the Parties agree as follows:

 

		1.	Section 2 of Appendix E (Royalties) of the Agreement: Reference to “30%”
is hereby replaced with “15%”.

 

Attached hereto as Annex A is the amended
Appendix E.

 

		2.	In consideration for the reduction of
                                         royalties, as set forth in Section 1 above, Intec Pharma shall grant shares as
                                         set forth in the following provision, which shall be added to the Agreement as Section
                                         7A (after Section 7g):

 

“7A Additional Consideration.
In consideration for the grant of License, and in addition to the consideration set forth in Section 7(a), the Company shall
grant 746 Ordinary Shares thereof, par value NIS 0.01 each (which amount of shares is equal to 1% of Intec Pharma’s issued and
outstanding share capital on the date hereof) to each of the following: Yissum, Prof Michael Friedman and Prof Amnon Hoffman. Such
grant of shares is subject to (i) the execution by such grantees of any document reasonably required by Intec Pharma in order to
effectuate the grant; and (ii) payment by the grantees of the par value of the shares, as required by law.

 

		3.	Except as explicitly set forth in this Amendment, all other terms and provisions of the Agreement
shall remain in full force and effect. In the event of contradiction between any term herein and that of the Agreement, this Amendment
shall prevail.

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the Parties hereto have caused this Amendment
to be executed by their duly authorized representatives.

 

	Yissum Research Development	 	Intec Pharmaceutical Partnership	 
	Company of the Hebrew	 	Ltd.	 
	University of Jerusalem 	 	 	 
	 	 	 	 
	Signature:	/s/ Abraham Barak	 	Signature:	/s/ Zvi Joseph	 
	 	 	 	 	 	 
	Name:	 Abraham Barak	 	Name:	 Zvi Joseph	 
	 	 	 	 	 	 
	Title:	President and CEO	 	Title:	Chairman	 

 

Each of
the undersigned hereby confirm, with respect to himself, that (i) he has read the Agreement as herein amended; and (ii) agrees
to the provisions of Section 2 of this Amendment, to that extent they apply thereto.

 

	/s/ Michael Friedman	 	/s/ Amnon Hoffman	 
	Prof. Michael Friedman	 	Prof. Amnon Hoffman	 
	 	 	 	 
	14/7/05	 	14/7/05	 
	Date	 	Date	 

 

    	2

    	 

    

 

APPENDIX E - ROYALTIES

 

1.         The Company will pay to Yissum 3% royalties from the net
sales of the products from the first date of commercial sale in each country.

 

2.         The Company shall be required to pay Yissum 15% of any
payment or benefit of any sort or nature the Company may receive from the Sub-License.

 

    	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]